These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23018371)

  • 1. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
    Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
    J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
    Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
    J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS penetration of ART in HIV-infected children.
    Van den Hof M; Blokhuis C; Cohen S; Scherpbier HJ; Wit FWNM; Pistorius MCM; Kootstra NA; Teunissen CE; Mathot RAA; Pajkrt D
    J Antimicrob Chemother; 2018 Feb; 73(2):484-489. PubMed ID: 29126299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
    Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
    AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".
    Calcagno A; D'Avolio A; Di Perri G; Bonora S
    J Acquir Immune Defic Syndr; 2013 Apr; 62(4):e118-9. PubMed ID: 24135736
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".
    Cusini A; Ledergerber B; Widmer N; Günthard HF
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):e14-5. PubMed ID: 24047974
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
    Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
    Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
    Delille CA; Pruett ST; Marconi VC; Lennox JL; Armstrong WS; Arrendale RF; Sheth AN; Easley KA; Acosta EP; Vunnava A; Ofotokun I
    J Clin Pharmacol; 2014 Sep; 54(9):1063-71. PubMed ID: 24691856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
    Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
    Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
    Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
    J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
    Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
    Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
    AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.